Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) Shares Outstanding (Diluted Average) (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Shares Outstanding (Diluted Average) for 10 consecutive years, with $8.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 5.58% year-over-year to $8.9 million, compared with a TTM value of $8.9 million through Sep 2025, up 5.58%, and an annual FY2024 reading of $8.5 million, up 2.48% over the prior year.
  • Shares Outstanding (Diluted Average) was $8.9 million for Q3 2025 at Sanara MedTech, up from $8.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $8.9 million in Q3 2025 and bottomed at $7.8 million in Q3 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $8.3 million, with a median of $8.4 million recorded in 2023.
  • Peak annual rise in Shares Outstanding (Diluted Average) hit 6.32% in 2023, while the deepest fall reached 0.46% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $7.9 million in 2022, then rose by 4.71% to $8.3 million in 2023, then grew by 2.48% to $8.5 million in 2024, then grew by 5.38% to $8.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SMTI at $8.9 million in Q3 2025, $8.6 million in Q2 2025, and $8.6 million in Q1 2025.